Formulation: A solid
Formal Name: L-leucyl-L-seryl-L-threonyl-L-alanyl-L-alanyl-L-α-aspartyl-L-methionyl-L-glutaminylglycyl-L-valyl-L-valyl-L-threonyl-L-α-aspartylglycyl-L-methionyl-L-alanyl-L-serylglycyl-L-leucyl-L-α-aspartyl-L-lysyl-L-α-aspartyl-L-tyrosyl-L-leucyl-L-lysyl-L-prolyl-L-α-aspartyl-L-aspartic acid, trifluoroacetate salt
Purity: ≥95%
Formula Markup: C122H197N31O47S2 • XCF3COOH
Formula Weight: 2914,2
Shelf life (days): 1460
Notes: Azurin (50-77) is a peptide fragment of the copper-containing bacterial protein azurin, which is found in P. aeruginosa, and has cell cycle arrest, cancer proliferation, and angiogenesis-regulating activities.{49807,49808} It is an inhibitor of VEGFR2 (IC20 = ~10.7 µM).{49808} Azurin (50-77) (20 µM) induces cell cycle arrest at the G2/M phase in MCF-7 breast cancer cells. It reduces MCF-7 and ZR-75-1 breast cancer cell proliferation when used at a concentration of 50 µM. Azurin (50-77) reduces VEGF-A-induced capillary tube formation (IC50 = 12 µM), as well as decreases cell membrane-associated levels of F-actin, focal adhesion kinase (FAK), and paxillin and increases extracellular levels of platelet endothelial cell adhesion molecule-1 (PECAM-1) in human umbilical vein endothelial cells (HUVECs) when used at a concentration of 25 µM.{49808} In vivo, azurin (50-77) (10 mg/kg per day) reduces tumor volume in an MCF-7 mouse xenograft model.{49807}
English
Deutsch
